Showing 4591-4600 of 8204 results for "".
- Data Show Long-term Safety, Clinical Benefit of Dupilumab in Pediatric ADhttps://practicaldermatology.com/news/data-show-long-term-safety-clinical-benefit-of-dupilumab-in-pediatric-ad/2460757/Dupilumab (Dupixent, Sanofi/Regeneron) is safe and effective for the long-term management of atopic dermatitis in patients as young as six, data from a collection of posters presented at the AAD 2021 VMX show. One study
- Favorable 5-Year Data for Janssen’s Tremfya in PsOhttps://practicaldermatology.com/news/favorable-5-year-data-for-janssens-tremfya-in-pso/2460758/Newly presented phase 3 data show that Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years. Treatment impro
- DermTech Launches DermTech PLAplushttps://practicaldermatology.com/news/dermtech-launches-dermtech-plaplus/2460759/DermTech has launched DermTech PLAplus (TM), its next generation test for the enhanced early detection of melanoma, intended to provide objective and actionable information to guide clinical management decisions for skin lesions suspicious of melanoma.
- C-Jun Protein May Play Role in Psoriasis Developmenthttps://practicaldermatology.com/news/c-jun-protein-may-play-role-in-psoriasis-development/2460753/The "c-Jun" protein may play a major role in the development of psoriasis, but inhibiting this protein may alleviate symptoms, new research suggests. c-Jun belongs to a larger family of transcription factors, DNA-binding factors, known as Activator Protein-1 (AP-1). Previ
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- DecisionDx-Melanoma Accurately Predicts Patient Outcomes in Cutaneous Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-accurately-predicts-patient-outcomes-in-cutaneous-melanoma/2460746/Castle Biosciences, Inc.’s DecisionDx-Melanoma is a significant, independent predictor of patient outcomes in cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutane
- Industry Optimism Surges: Three Ways for Dermatologists to Capitalizehttps://practicaldermatology.com/news/industry-optimism-surges-three-way-for-dermatologists-to-capitalize/2460745/Despite a tumultuous past year, a recent Medscape survey shows that 85 percent of dermatologists are happy with their profession and optimistic about the future. This optimism is likely brought on by
- Thiazide Diuretics Linked to Skin Cancer Riskhttps://practicaldermatology.com/news/thiazide-diuretics-linked-to-skin-cancer-risk/2460744/Use of certain blood pressure-lowering medications may increase risk for skin cancer, a new study shows. Researchers reviewed data for nearly 303,000 adults in Ontario over age 65 who were prescribed medications for high bl
- Expert Opinion: Fleshing Out the Role of Biosimilars in Dermatologyhttps://practicaldermatology.com/news/expert-opinion-fleshing-out-the-role-of-biosimilars-in-dermatology/2460742/Two new studies of biosimilars of tumor necrosis factor blockers that are used to treat a number of dermatologic conditions suggest that they are equivalent to their originator drugs, but there may be more involved in making the decision about switching to a biosimilar than lower cost.
- Practical Dermatology Magazine Mourns the Passing of Two Preeminent Dermatologistshttps://practicaldermatology.com/news/practical-dermatology-mourns-the-passing-of-two-preeminent-dermatologists/2460741/By Wendy Lewis It is with great sadness that Practical Dermatology® magazine pays our respects to two very talented and respected dermatologists, Melanie Grossman, MD and Marta Rendon, MD.